Firms

BNP Paribas Asset Management Alts

BNP Paribas Asset Management Alts

Puteaux, France

alts.axa-im.com

BNP Paribas Asset Management Alts, formerly AXA IM Alts, is the alternative investments platform of BNP Paribas Asset Management. It invests across private equity, infrastructure, real estate and alternative credit, using equity and debt to finance companies, buildings and essential infrastructure. Its impact investing programmes focus on affordable healthcare, financial inclusion, climate innovation, biodiversity and natural capital, alongside commercial investment returns. The global healthcare private equity strategy backs late-stage clinical development and early commercialization of medical devices, diagnostics, drugs and vaccines designed to be effective, durable and affordable in both high-income and lower-resource markets. It typically leads or co-leads investments and supports clinical development, regulatory pathways, manufacturing and international market access. Its therapeutic interests include maternal and child health, vision, infectious diseases, diabetes, respiratory disease, cardiovascular care and oncology. The current platform combines AXA IM Alts, BNP Paribas Private Markets and BNP Paribas Real Estate Investment Management activities following BNP Paribas’s acquisition of AXA Investment Managers in July 2025. Its investment teams and governance represent an operating platform spanning legal entities, rather than the parent bank or AXA Venture Partners.

Founded
—
Type
Venture capital

Funds3

  • European Junior Infra Debt Fund II€1.2B

    European Junior Infra Debt Fund II provides senior and junior secured fixed- and floating-rate debt for European renewable energy, utilities, digital infrastructure, clean mobility and social infrastructure. Launched in August 2024, it announced a final close with approximately EUR1.2 billion of commitments in September 2026. Its Article 8 SFDR approach integrates ESG criteria and targets defensive income through infrastructure financing.

  • BNP Paribas Agility Co-Invest Fund 2—

    BNP Paribas Agility Co-Invest Fund 2 makes private equity co-investments alongside European buyout managers, focusing on mid-cap companies across diversified industries and geographies. It supports co-underwriting and post-signing syndications, with published investment ranges of EUR10–50 million and a target portfolio of around fifty companies. Launched in 2024, its final close was announced in June 2026 with more than EUR960 million committed; the exact closing corpus is undisclosed.

  • Partner Capital Solutions 9 Fund (PCS9)€1.2B

    Partner Capital Solutions 9 is a significant risk transfer fund announced at final close with approximately EUR1.2 billion raised. The strategy invests in bank regulatory capital transactions referencing diversified performing corporate and financial-institution loan portfolios. Parallel separate managed account mandates are distinct from this fund’s capital.

Team

Arjun Kandola

BNP Paribas Asset Management Alts, Investment Associate of Healthcare Private Equity

—— – —

Operations and support

Alanna GreenInvestment Analyst of Healthcare Private Equity
Alexandre Martin-MinManaging Partner; Head of Natural Capital & Impact Investments; Chair of Healthcare Investment Committee
Anne BonCOO and Co-Head of Business Development/Structuring, Structured Finance & Impact Private Equity
Cameron IrbyAssociate, Healthcare Private Equity
Camila Alva EstabridisAssociate, Impact Investing
Christophe FritschGlobal Head of Alternative Credit; Member of Management Board
Curt LaBellePartner, Head of Healthcare Private Equity
Damien FournierCo-Head, Agility Co-Invest Strategy
Daniel BradburyHealthcare Strategy Key Advisor — Investor, Entrepreneur, Operator and Board Member
Déborah ShireDeputy Head, BNPP AM Alts; Member of Management Board
Frederick St GoarHealthcare Strategy Key Advisor — Cardiology specialist
Harry WatersDirector, Fund Management
Isabelle ScemamaGlobal Head, BNPP AM Alts; Chair of Management Board; Member of Real Estate and Infrastructure Investment Committees
Jalel KallelPrincipal, Private Equity Transactions
James FeeneyAssociate, Fund Management
John O’DriscollGlobal Co-Head of Real Estate; Global Co-Head of Investment Management (REIM); Chair of Strategic Investment Committee; Member of Management Board
Jonathan DeanHead of Fund Management; Voting Investment Committee Member (Impact Investing)
Karen AzoulayHead of Real Assets
Lionel GomezCo-Head, Agility Co-Invest Strategy
Mads DallHealthcare Strategy Key Advisor — Diabetes, business development/commercial specialist and investor
Marie-Christine BisseryHealthcare Strategy Key Advisor — Oncology specialist
Mark GilliganHead of Infrastructure; Member of Management Board
Mark SullivanHealthcare Strategy Key Advisor — Global health specialist
Niel LateganSenior Analyst, Operational Due Diligence
Niti PallHealthcare Strategy Key Advisor — Global health specialist
Pascal ChristoryGlobal Head of Private Equity, BNPP AM Alts
Renuka GaddeHealthcare Strategy Key Advisor — Global Health and MedTech specialist
Rob BinneyHealthcare Strategy Key Advisor — Medical device commercial specialist
Romain BoullandDirector
Shacey PetrovicHealthcare Strategy Key Advisor — Diabetes and women's health business specialist
Shade DuffyPrincipal, Impact Investing; Director of Impact Management (individual-profile title)
Susan MacDonaldHealthcare Strategy Key Advisor — Clinical Ophthalmology specialist
Timothée RaulyGlobal Co-Head of Real Estate; Global Co-Head of Investment Management (REIM); Member of Management Board
Zina Affas BessePartner, Deputy Head of Healthcare Private Equity

Co-investing

Avestria Ventures
Laerdal Million Lives Fund
RH Capital

Investments